<DOC>
	<DOC>NCT00567996</DOC>
	<brief_summary>This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.</brief_summary>
	<brief_title>Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Clinical diagnosis of moderate to severe Chronic Obstructive Pulmonary Disease (COPD) as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 Guidelines (mandatory) and including: Smoking history of at least 20 pack years Postbronchodilator Forced Expiratory Volume in 1 second (FEV1) &lt; 80% predicted and &gt;or= 30% of predicted normal value Postbronchodilator FEV1/FVC &lt; 70% ("Post" defined as within 30 minutes of inhalation of 400 Âµg salbutamol) Pregnant or nursing (lactating) women and women of childbearing potential UNLESS they meet prespecified definitions of postmenopausal or are using prespecified acceptable methods of contraception Hospitalisation for COPD exacerbation in the 6 weeks prior to Visit 1 or during runin Patients requiring oxygen therapy for chronic hypoxemia (typically &gt;15h/day) Respiratory tract infection within 6 weeks prior to Visit 1 and during the runin period Concomitant pulmonary disease Asthma history (eosinophils &gt; 400/mm3; symptoms prior to age 40). Includes history of childhood asthma History of long QTc syndrome or QTc interval &gt; 450 ms for males and &gt;470 ms for females Patients who have a clinically significant condition or a clinically relevant laboratory abnormality History of reactions to sympathomimetic amines or inhaled medication Inability to use the dry powder devices or perform spirometry Irregular day/night, wake/sleep cycles, e.g. shift workers Certain medications for COPD and allied conditions such as long acting bronchodilators must not be used prior to Visit 1 and for a prespecified minimum washout period Patients unable or unwilling to complete a patient diary Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Chronic obstructive pulmonary disease, indacaterol, salmeterol, placebo controlled</keyword>
</DOC>